Clinical Nutrition Research Center, Illinois Institute of Technology
Phase
Not applicable
Started
2025-04-14
Last updated
2026-08-28
Condition(s) studied
Pre Diabetes
Investigational drug(s) / intervention(s)
MangoControl Beverage
Mango: Mango beverage
Control Beverage: Italian Ice beverage
Study summary
The purpose of this study is to investigate the effect of mango intake on metabolic and inflammatory responses relative to meals in individuals at risk of developing diabetes, as well as to understand how the beneficial compounds found in mangoes are absorbed and processed in the body.
Eligibility
Sex
ALL
Min age
20 Years
Max age
60 Years
Healthy volunteers
Accepted
Inclusion Criteria:
* Be between 20-60 years old.
* Have a BMI of 25-35 kilograms per square meter.
* Have fasting blood glucose between 100-125 milligrams per deciliter or Glycated hemoglobin (HbA1c) between 5.7-6.4%.
* Be non-smokers for at least 12 months.
* Be generally healthy, with no major organ-related diseases.
* Not take medications or supplements that could interfere with the study.
* Be able to follow study procedures, including dietary restrictions and scheduled visits.
Exclusion Criteria:
* Smoke, vape, or use marijuana.
* Have allergies or intolerance to mangoes or study foods.
* Have blood pressure above 160/100 millimeters of Mercury.
* Have fasting blood glucose above 125 milligrams per deciliter.
* Have a history of major heart disease, stroke, or cancer in the past five years.
* Be pregnant, planning to become pregnant, or breastfeeding.
* Take anti-inflammatory drugs or certain dietary supplements.
* Have had major surgery or trauma in the past two months.
* Follow extreme diets (e.g., vegan, Atkins).
* Have used antibiotics in the last six weeks.
* Have a history of eating disorders or substance abuse in the past two years.
* Drink more than three cups of coffee or tea per day.
* Have donated blood in the last three months.
* Be professional athletes or do excessive exercise.
* Have had weight changes of more than 11 pounds in the past two months.
* Work overnight shifts.
Primary outcome measure(s)
Change in postprandial glucose — 7 hours Change in postprandial glucose as measured by absolute values and calculated insulin sensitivity using homeostasis model assessment of fasting insulin sensitivity (HOMA-%S) and B-cell function (HOMA-%).
Change in postprandial glucose through peripheral insulin sensitivity — 7 hours Change in postprandial glucose as measured by assessment of peripheral insulin sensitivity using Matsuda index.
Change in postprandial insulin — 7 hours Change in postprandial insulin as measured by absolute values and calculated insulin sensitivity using homeostasis model assessment of fasting insulin sensitivity (HOMA-%S) and B-cell function (HOMA-%).
Change in postprandial insulin through peripheral insulin sensitivity — 7 hours Change in postprandial insulin as measured by assessment of peripheral insulin sensitivity using Matsuda index.
Evaluate Interleukin-6 (IL-6) as an index of systemic inflammatory response — 7 hours Assessments to address this aim will include analysis of systemic markers of inflammation (IL-6) in plasma using ELISA method
Evaluate Tumor Necrosis Factor-alpha (TNF-α) as an index of systemic inflammatory response — 7 hours Assessments to address this aim will include analysis of systemic markers of inflammation (TNF-α) in plasma using ELISA method
Trial sites (1)
Facility
City
Region
Status
Clinical Nutrition Research Center
Chicago
Illinois
More Clinical Nutrition Research Center, Illinois Institute of Technology trials in the USA
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.